NationStates Jolt Archive


New Product for International Trade

Mauiwowee
08-06-2004, 06:43
[ :idea: :!: AS COOL AS THIS SOUNDS, PLEASE NOTE IT IS ALL MADE UP STUFF! DON'T TRY TO ORDER THIS OR GET YOU DOCTOR TO PRESCRIBE IT![:idea: :!:

The Kingdom of Mauiwowee anounces the availability of the following product of its pharmacutical industry for trade in the international community. The below reproduced pharmocological information is the result of 4 years of extreme product testing by the former private company, Marinol, Inc. (nationalized by the gov. of Mauiwowee upon our independence day of June 7, 2004). The drug is subject and MDA (Mauiwowee Drug Agency) testing for purity upon shipping.


Cocaninol (kO-CAN-i-Nol)
Brand name: Cocahuana (kO-k-WHa-nA)
--------------------------------------------------------------------------------

Pharmacology
Analgesic (local & systemwide)

Cocaninol: a Coca plant based combination of a Cocaine based 2Beta-carbomethoxy-3Beta-benzoxytropane (C17H21NO4) (a/k/a Cocaine) with Marinol (a/k/a Marinol or THC) product.
It binds with high affinity to the GABA pain receptor complex. Considerable evidence suggest that the central pharmacologic/therapeutic actions of Cocaninol are mediated via interaction with this receptor complex.

Orally administered: it is readily absorbed in man with peak plasma concentrations occurring 1 to 2 hours following administration. The half life range is 6 to 20 days following single dose administration depending on liver function and alcohol consumption. With multiple doses, given 3 times daily, steady state is reached within 4 days. Cocaninol and its metabolites are excreted primarily in the urine and is detectable in the urine for up to 35 days after discontinuation due to its binding properties with fat. Degradation occurs mainly by oxidation yielding the primary and secondary metabolites which are active and appear to have half-lives similar to smoked, raw marijuana, but are present at only low levels in the plasma. Cocaninol is 85% fat cell bound.

Topically administered: it is readily absorbed by open/exposed nerve endings in a concentration (60/40 Cocaninol/Water) that destroys or interferes (research is ongoing) with the GABA nerve ending ability to communicate with the brain's pain receptors for approximately 2 hours (depending on the concentration used). Further, in extreme and repeated (5 times per day or greater) topical concentrations it appears, in a blind study, to have the same effect, though of shorter duration, of oral administration.

Cocaninol (500 mcg (0.5 mg)), administered 3 times a day for 14 days, did not affect prothrombin times or plasma warfarin levels in male volunteers administered sodium warfarin orally save and except as those levels impact upon Cocaninol concentration in a body's natural fat.
--------------------------------------------------------------------------------

Indications
For the management of pain (including both local (topical applications) and system-wide (on an ongoing prescribed basis)). Cocaninol is also indicated for the treatment of Generalized Anxiety Disorder (GAD) and for the management of panic disorder with or without agoraphobia (full testing and approval on this use of Cocaninol awaits government approval).
--------------------------------------------------------------------------------

Contraindications
Hypersensitivity to Coca or Hemp/marijuana products (such as Cocaine or Marinol) or those with Asthma, or hypertension (High Blood Pressure). Special Contradiction: Patients diagnosed with Schizophrenia should not take Cocaninol under ANY circumstance!
--------------------------------------------------------------------------------

Warnings
Cocaninol is not recommended for use in patients whose primary diagnosis is psychosis, schizophrenia or depression.

Occupational Hazards
As with other potentially CNS depressant drugs, patients should be cautioned against activities requiring mental alertness, judgement and physical coordination such as driving or operating machinery, particularly in the early phases of treatment and until proper adjustment to side effects has been established. Alcohol and benzodiazepines should never be mixed when driving because of the unpredictable CNS depressant effects of this combination.

Pregnancy
Safety in pregnancy has not been established, therefore its use is not recommended. Since Cocaninol is an analgesic derivative, its administration is rarely justified in women of childbearing potential. If the drug is prescribed to a woman of child bearing potential she should be warned to consult her physician regarding the use of the drug if she intends to become or suspects that she is pregnant.

Lactation
Studies in rats have indicated that Cocaninol and its metabolites are secreted into the milk. Therefore, nursing should not be undertaken while a patient is receiving the drug.

How Supplied

1. In powder form to be mixed with sterile water and administered as a topical analgesic (i.e. mixed with water and placed on a cotton swab and placed inside the nostril for it numbing effect and to control pain during nasal surgery) (1gram per tsp recommended concentration).

2. In pill form (0.5 mg pills X 3-4 times per day) to be used on an ongoing basis (subject to the foregoing warnings and full prescribing informational publication) for the management of pain/nausea related to the use of chemotherapy in the treatment of cancer patients and those with intractible (but readily diagnosed and observable) pain.




[ :idea: :!: AS COOL AS THIS SOUNDS, PLEASE NOTE IT IS ALL MADE UP STUFF! DON'T TRY TO ORDER THIS OR GET YOU DOCTOR TO PRESCRIBE IT![:idea: :!: